[go: up one dir, main page]

EP1146790A4 - Compounds and methods - Google Patents

Compounds and methods

Info

Publication number
EP1146790A4
EP1146790A4 EP00909984A EP00909984A EP1146790A4 EP 1146790 A4 EP1146790 A4 EP 1146790A4 EP 00909984 A EP00909984 A EP 00909984A EP 00909984 A EP00909984 A EP 00909984A EP 1146790 A4 EP1146790 A4 EP 1146790A4
Authority
EP
European Patent Office
Prior art keywords
compounds
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00909984A
Other languages
German (de)
French (fr)
Other versions
EP1146790A1 (en
Inventor
William E Bondinell
Michael J Neeb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1146790A1 publication Critical patent/EP1146790A1/en
Publication of EP1146790A4 publication Critical patent/EP1146790A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
EP00909984A 1999-01-25 2000-01-25 Compounds and methods Withdrawn EP1146790A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11704499P 1999-01-25 1999-01-25
US117044P 1999-01-25
PCT/US2000/001908 WO2000042852A1 (en) 1999-01-25 2000-01-25 Compounds and methods

Publications (2)

Publication Number Publication Date
EP1146790A1 EP1146790A1 (en) 2001-10-24
EP1146790A4 true EP1146790A4 (en) 2004-03-17

Family

ID=22370713

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00909984A Withdrawn EP1146790A4 (en) 1999-01-25 2000-01-25 Compounds and methods

Country Status (4)

Country Link
EP (1) EP1146790A4 (en)
JP (1) JP2002535256A (en)
AU (1) AU3215500A (en)
WO (1) WO2000042852A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1313477A4 (en) * 2000-07-15 2004-03-03 Smithkline Beecham Corp Compounds and methods
EP1752455B1 (en) 2000-09-15 2010-11-10 Anormed Inc. Chemokine receptor binding heterocyclic compounds
RU2297413C2 (en) * 2000-09-15 2007-04-20 Анормед, Инк. Heterocyclic compounds modulating activity of chemokine receptor, their using and pharmaceutical composition containing thereof
SG126006A1 (en) 2000-09-15 2006-10-30 Anormed Inc Chemokine receptor binding heterocyclic compounds
DE60137944D1 (en) * 2000-09-15 2009-04-23 Anormed Inc CHEMOKIN RECEPTOR BINDING HETEROCYCLIC COMPOUNDS
WO2002034760A2 (en) * 2000-10-23 2002-05-02 Smithkline Beecham Corporation Compounds and methods
WO2003061659A1 (en) * 2002-01-22 2003-07-31 Merck & Co., Inc. Treating stress response with chemokine receptor ccr5 modulators
US7262194B2 (en) 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US20060019977A1 (en) * 2002-10-18 2006-01-26 Ono Pharmaceutical Co., Ltd. Spiroheterocyclic derivative compounds and drugs comprising the compound as the active ingredient
NZ542304A (en) 2003-03-14 2009-07-31 Ono Pharmaceutical Co Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
US7498323B2 (en) 2003-04-18 2009-03-03 Ono Pharmaceuticals Co., Ltd. Spiro-piperidine compounds and medicinal use thereof
EP1616862A4 (en) * 2003-04-18 2008-07-16 Ono Pharmaceutical Co Nitrogenous heterocyclic compound and use thereof
GEP20094675B (en) 2003-07-24 2009-05-10 Euro Celtique Sa Heteroaryl- tetra-hydropiperidyl compounds useful for treating or preventing pain
RU2006146985A (en) 2004-05-28 2008-07-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) MUSCARINE RECEPTOR MODULATORS
ES2457041T3 (en) 2004-09-13 2014-04-24 Ono Pharmaceutical Co., Ltd. N-4-piperidylurea derivatives and medicines containing them as active ingredient
WO2006088836A2 (en) * 2005-02-16 2006-08-24 Schering Corporation Piperazine-piperidines with cxcr3 antagonist activity
US20110052612A1 (en) 2005-05-31 2011-03-03 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
PL1942108T3 (en) 2005-10-28 2014-03-31 Ono Pharmaceutical Co Compound containing basic group and use thereof
DK1961744T3 (en) 2005-11-18 2013-07-15 Ono Pharmaceutical Co Compound containing basic groups and their use
BRPI0708731A2 (en) 2006-03-10 2011-06-07 Ono Pharmaceutical Co nitrogenous heterocyclic derivative, and pharmaceutical agent comprising the derivative as an active ingredient
JP5257068B2 (en) 2006-05-16 2013-08-07 小野薬品工業株式会社 Compound containing acidic group which may be protected and use thereof
US20090325992A1 (en) 2006-07-31 2009-12-31 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
PT2142529E (en) 2007-04-27 2014-03-20 Purdue Pharma Lp Trpv1 antagonists and uses thereof
CA2756870A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted indolo-pyridinone compounds
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
EP2575815A4 (en) 2010-06-04 2013-12-25 Albany Molecular Res Inc Glycine transporter-1 inhibitors, methods of making them, and uses thereof
EP2642998B1 (en) 2010-11-24 2020-09-16 The Trustees of Columbia University in the City of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
ES2620528T3 (en) 2011-06-22 2017-06-28 Purdue Pharma Lp TRPV1 antagonists that include a dihydroxy substituent and uses thereof
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
WO2013166037A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of eye disorders
WO2014152013A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
WO2014151959A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
EP2968303B1 (en) 2013-03-14 2018-07-04 The Trustees of Columbia University in the City of New York Octahydrocyclopentapyrroles, their preparation and use
AU2015253232B2 (en) 2014-04-30 2020-10-01 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36616A (en) * 1970-06-01 1975-02-10 Lepetit Spa Antiviral compositions containing 1-amino-piperazine derivatives
EP0524146A1 (en) * 1991-07-19 1993-01-20 Ciba-Geigy Ag Aminosubstituted Piperazinederivatives
FR2758328B1 (en) * 1997-01-15 1999-04-02 Pf Medicament NEW AROMATIC AMINES DERIVED FROM CYCLIC AMINES USEFUL AS MEDICAMENTS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO0042852A1 *

Also Published As

Publication number Publication date
AU3215500A (en) 2000-08-07
WO2000042852A1 (en) 2000-07-27
EP1146790A1 (en) 2001-10-24
JP2002535256A (en) 2002-10-22

Similar Documents

Publication Publication Date Title
EP1146790A4 (en) Compounds and methods
EP1223932A4 (en) Compounds and methods
DE50002490D1 (en) Polyester-polyetherblockcopolymere
EP1102535A4 (en) Compounds and methods
DE50008011D1 (en) Thixotropierungsmittel
EP1313477A4 (en) Compounds and methods
DE50002614D1 (en) Sigma-delta-modulator
EP1274424A4 (en) Compounds and methods
GB9903584D0 (en) Modified calycins
DE50000137D1 (en) Spirofluorenopyrane
GB9926161D0 (en) Methods
GB9905817D0 (en) Methods
DE10081629D2 (en) Seilzugbefestigung
AU140373S (en) Bumbag
AU141428S (en) Turnpiece
EP1343796A4 (en) Compounds and methods
DE50005334D1 (en) Tricyclische benzoylcyclohexandion-derivate
GB9914943D0 (en) Methods
GB9908525D0 (en) Methods
GB9923117D0 (en) Insect-paper and methods for its formation and use
GB9919362D0 (en) Novel method and compounds
GB9916675D0 (en) Enigma-sip and enigma-cell
EG22401A (en) Set 3c1-strong
GB9914733D0 (en) Methods
GB9905080D0 (en) Methods

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010816

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040204

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/496 B

Ipc: 7A 61K 31/495 B

Ipc: 7A 01N 43/58 A

Ipc: 7A 61K 31/4418 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051209